Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | EVP, Corp and Development Ops | August 31, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IONIS PHARMACEUTICALS INC
Report date August 31, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,883 |
Reported balance
After 2026-08-31 transaction · row 1
1 source rowRow 1 · 2026-08-31 · Other · Acquired 58 · Balance 102,883 F1: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 3, 2026 00:22 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 58 | $51.31 | $2,975.75 |
DisclosureSEC source: 0000874015-26-000259 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,883 F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 23:19 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 973 | $75.04 | $73,015.87 |
DisclosureSEC source: 0000874015-26-000170 · edgardoc.xml · nonDerivative · entry 2 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.01 to $75.06 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 23:19 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 1,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000170 · edgardoc.xml · derivative · entry 3 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,926 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 23:19 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000170 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 22:28 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 351 | $48.87 | $17,152.14 |
DisclosureSEC source: 0000874015-26-000122 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,598 F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 27, 2026. These shares may not be sold until August 27, 2026. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 01:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 6,179 | $83.03 | $513,047.93 |
DisclosureSEC source: 0000874015-26-000097 · edgardoc.xml · nonDerivative · entry 2 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,247 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.00 to $83.08 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 01:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantCommon Stock | 11,991 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000097 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,426 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the performance period of the grant to the reporting person reported on January 18, 2023. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 167.27% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 200% based on actual achievement of the goal. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 8,480 | $75.11 | $636,932.80 |
DisclosureSEC source: 0000874015-26-000063 · edgardoc.xml · nonDerivative · entry 2 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,435 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.07 to $75.14 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 9,675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000063 · edgardoc.xml · derivative · entry 5 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,801 Underlying: Common Stock · 9,675 shares Expires not disclosed F8 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 20,089 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000063 · edgardoc.xml · derivative · entry 4 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,126 Underlying: Common Stock · 20,089 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantPerformance Restricted Stock Units · Derivative | 25,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000063 · edgardoc.xml · derivative · entry 3 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,138 Underlying: Common Stock · 25,800 shares Expires not disclosed F4 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F5 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. F5 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 20,089 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000063 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,350 | $0.00 Strike: $79.67 | $0.00 |
DisclosureSEC source: 0000874015-26-000018 · edgardoc.xml · derivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,350 Underlying: Common Stock · 19,350 shares Expires 2036-01-01 F1 · derivative.exercise_date: Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 22:13 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 8,000 | $76.17 | $609,379.20 |
DisclosureSEC source: 0000874015-25-000278 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,826 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.00 to $76.32 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 00:15 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,425 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-25-000259 · edgardoc.xml · derivative · entry 6 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,425 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 00:15 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 12,425 | $72.23 | $897,398.11 |
DisclosureSEC source: 0000874015-25-000259 · edgardoc.xml · nonDerivative · entry 4 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,826 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 12, 2024. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.46, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 00:15 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 12,425 | $53.77 | $668,092.25 |
DisclosureSEC source: 0000874015-25-000259 · edgardoc.xml · nonDerivative · entry 3 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2025 Filed Oct 17, 2025 00:15 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,475 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-25-000259 · edgardoc.xml · derivative · entry 5 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,425 Underlying: Common Stock · 11,475 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2025 Filed Oct 17, 2025 00:15 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 11,475 | $72.03 | $826,589.00 |
DisclosureSEC source: 0000874015-25-000259 · edgardoc.xml · nonDerivative · entry 2 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,826 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 12, 2024. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.115, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4. Read SEC document |
| October 14, 2025 Filed Oct 17, 2025 00:15 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 11,475 | $53.77 | $617,010.75 |
DisclosureSEC source: 0000874015-25-000259 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 22:26 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 166 | $27.71 | $4,599.86 |
DisclosureSEC source: 0000874015-25-000187 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,826 F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 29, 2025. These shares may not be sold until March 2, 2026. Read SEC document |
| April 16, 2025 Filed Apr 17, 2025 20:53 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 680 | $28.37 | $19,291.60 |
DisclosureSEC source: 0000874015-25-000120 · edgardoc.xml · nonDerivative · entry 2 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,660 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 20:53 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 1,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000120 · edgardoc.xml · derivative · entry 3 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,215 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 20:53 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000120 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 414 | $28.21 | $11,679.56 |
DisclosureSEC source: 0000874015-25-000099 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,465 F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 28,2025. These shares may not be sold until August 28, 2025. Read SEC document |
| January 16, 2025 Filed Jan 18, 2025 00:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,400 | $32.70 | $176,580.00 |
DisclosureSEC source: 0000874015-25-000057 · edgardoc.xml · nonDerivative · entry 2 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,051 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 14,283 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000057 · edgardoc.xml · derivative · entry 5 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,090 Underlying: Common Stock · 14,283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 33,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000057 · edgardoc.xml · derivative · entry 4 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,373 Underlying: Common Stock · 33,000 shares Expires not disclosed F5 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantPerformance Restricted Stock Units · Derivative | 22,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000057 · edgardoc.xml · derivative · entry 3 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,338 Underlying: Common Stock · 22,000 shares Expires not disclosed F3 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F4 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. F4 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 14,283 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000057 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:52 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $34.69 | $0.00 |
DisclosureSEC source: 0000874015-25-000017 · edgardoc.xml · derivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: Grant on 01/02/2025 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2025. 25% of the shares subject to the option will vest and become exercisable on 01/02/2026. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| August 30, 2024 Filed Sep 5, 2024 01:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 12 | $38.64 | $463.69 |
DisclosureSEC source: 0000874015-24-000216 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,168 F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 30, 2024. These shares may not be sold until February 28, 2025. Read SEC document |
| April 16, 2024 Filed Apr 17, 2024 21:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 905 | $41.66 | $37,698.23 |
DisclosureSEC source: 0000874015-24-000138 · edgardoc.xml · nonDerivative · entry 2 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,156 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.65 to $41.66 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 1,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-24-000138 · edgardoc.xml · derivative · entry 3 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,373 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-24-000138 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 00:13 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 604 | $34.43 | $20,792.70 |
DisclosureSEC source: 0000874015-24-000123 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · Vice President Level 14 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,186 F1 · kind: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 29, 2024. These shares may not be sold until August 31, 2024. Read SEC document |
| January 17, 2024 Filed Jan 18, 2024 22:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 4,497 | $50.42 | $226,725.25 |
DisclosureSEC source: 0000874015-24-000079 · edgardoc.xml · nonDerivative · entry 2 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,582 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.35 to $50.43, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 22:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 12,080 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-24-000079 · edgardoc.xml · derivative · entry 3 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,248 Underlying: Common Stock · 12,080 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 22:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 12,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-24-000079 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 15, 2024 Filed Jan 18, 2024 01:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 20,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-24-000051 · edgardoc.xml · derivative · entry 2 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,328 Underlying: Common Stock · 20,400 shares Expires not disclosed F3 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2024 Filed Jan 18, 2024 01:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantPerformance Restricted Stock Units · Derivative | 17,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-24-000051 · edgardoc.xml · derivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,338 Underlying: Common Stock · 17,000 shares Expires not disclosed F1 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. F2 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:23 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 27,200 | $0.00 Strike: $52.87 | $0.00 |
DisclosureSEC source: 0000874015-24-000019 · edgardoc.xml · derivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Stock · 27,200 shares Expires 2034-01-01 F1 · derivative.exercise_date: Grant on 01/02/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 22:54 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,500 | $0.00 Strike: $47.34 | $0.00 |
DisclosureSEC source: 0000874015-24-000004 · edgardoc.xml · derivative · entry 3 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,482 Underlying: Common Stock · 11,500 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 22:54 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Tax withholdingCommon Stock | 11,029 | $50.50 | $556,964.50 |
DisclosureSEC source: 0000874015-24-000004 · edgardoc.xml · nonDerivative · entry 2 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,999 F1 · kind: Represents a "net exercise" of outstanding stock options. The reporting person received 471 shares of common stock on net exercise of option to purchase 11,500 shares of common stock. Pursuant to the terms of the Company's 2011 Equity Incentive Plan, the Company withheld 11,029 shares of common stock underlying the option for payment of the exercise price and tax withholdings using the closing stock price on December 28, 2023 of $50.50. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 22:54 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 11,500 | $47.34 | $544,410.00 |
DisclosureSEC source: 0000874015-24-000004 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 00:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 672 | $36.50 | $24,529.61 |
DisclosureSEC source: 0000874015-23-000132 · edgardoc.xml · nonDerivative · entry 2 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,528 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.19 to $36.50953 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| April 17, 2023 Filed Apr 20, 2023 00:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 1,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-23-000132 · edgardoc.xml · derivative · entry 3 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,720 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| April 17, 2023 Filed Apr 20, 2023 00:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-23-000132 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.